# Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients

> **NCT05360537** · PHASE4 · COMPLETED · sponsor: **University of Palermo** · enrollment: 100 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Insulin Degludec / Liraglutide Injectable Product
- **DRUG:** Insulin Glargine

## Key facts

- **NCT ID:** NCT05360537
- **Lead sponsor:** University of Palermo
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-01
- **Primary completion:** 2021-12-01
- **Final completion:** 2022-04-20
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2023-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05360537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05360537, "Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05360537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*